CRISPR/Cas9 genome editing system was employed to delete NAT10 in DLBCL cells, of which sgNAT10#2 (NAT10 knockout, NAT10 KO) exhibited the highest efficacy (Figure 2A,B) and was selected for subsequent functional experiments. Here, NAT10 is linked to diffuse large B-cell lymphoma.